5/15
10:29 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Morgan Stanley from $10.00 to $4.00. They now have an "equal weight" rating on the stock.
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Morgan Stanley from $10.00 to $4.00. They now have an "equal weight" rating on the stock.
5/15
09:59 am
pacb
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases [Yahoo! Finance]
Low
Report
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases [Yahoo! Finance]
5/15
09:05 am
pacb
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
High
Report
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
5/15
12:06 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
5/13
09:19 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Piper Sandler from $6.50 to $2.00. They now have a "neutral" rating on the stock.
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Piper Sandler from $6.50 to $2.00. They now have a "neutral" rating on the stock.
5/11
08:49 am
pacb
Pacific Biosciences of California First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Pacific Biosciences of California First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
5/10
06:38 pm
pacb
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/10
03:41 pm
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Barclays PLC from $3.00 to $2.00. They now have an "equal weight" rating on the stock.
Low
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Barclays PLC from $3.00 to $2.00. They now have an "equal weight" rating on the stock.
5/10
01:02 pm
pacb
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up [Yahoo! Finance]
Low
Report
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up [Yahoo! Finance]
5/9
07:44 pm
pacb
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Low
Report
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
5/9
04:24 pm
pacb
PacBio Announces First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
PacBio Announces First Quarter 2024 Financial Results [Yahoo! Finance]
5/9
04:05 pm
pacb
PacBio Announces First Quarter 2024 Financial Results
Low
Report
PacBio Announces First Quarter 2024 Financial Results
5/7
02:05 pm
pacb
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings [Yahoo! Finance]
Low
Report
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings [Yahoo! Finance]
5/2
11:09 am
pacb
MedGenome announces de novo Genome Assembly and Annotation Grant winners for 2024 [Yahoo! Finance]
Low
Report
MedGenome announces de novo Genome Assembly and Annotation Grant winners for 2024 [Yahoo! Finance]
5/2
10:45 am
pacb
Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know [Yahoo! Finance]
Low
Report
Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know [Yahoo! Finance]
4/30
08:17 am
pacb
NewBiologix Launches Next-Generation Sequencing and Optical Mapping Platform to Drive the Next Wave of Biopharmaceutical Discoveries [Yahoo! Finance]
Low
Report
NewBiologix Launches Next-Generation Sequencing and Optical Mapping Platform to Drive the Next Wave of Biopharmaceutical Discoveries [Yahoo! Finance]
4/25
11:44 am
pacb
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks [Yahoo! Finance]
Medium
Report
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks [Yahoo! Finance]
4/23
02:09 pm
pacb
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
4/22
04:46 pm
pacb
Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting [Yahoo! Finance]
4/22
08:53 am
pacb
PacBio moved to Neutral at JPMorgan after guidance cut [Seeking Alpha]
Medium
Report
PacBio moved to Neutral at JPMorgan after guidance cut [Seeking Alpha]
4/22
08:08 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating.
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating.
4/18
01:18 pm
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
Neutral
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
4/18
08:06 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $2.50 price target on the stock, down previously from $7.00.
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $2.50 price target on the stock, down previously from $7.00.
4/18
08:04 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Scotiabank from $15.00 to $8.00. They now have a "sector outperform" rating on the stock.
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Scotiabank from $15.00 to $8.00. They now have a "sector outperform" rating on the stock.
4/18
06:54 am
pacb
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 18% [Yahoo! Finance]
Medium
Report
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 18% [Yahoo! Finance]